Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Machine, Furnitures, Fixtures & OtherOther Gross PP&E Adjustments
Ratios

Spyre Therapeutics (SYRE) Leases (2019 - 2023)

Spyre Therapeutics' Leases history spans 5 years, with the latest figure at $2.3 million for Q2 2023.

  • For Q2 2023, Leases fell 35.93% year-over-year to $2.3 million; the TTM value through Jun 2023 reached $2.3 million, down 35.93%, while the annual FY2022 figure was $3.4 million, 9.88% down from the prior year.
  • Leases reached $2.3 million in Q2 2023 per SYRE's latest filing, down from $3.3 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $5.0 million in Q2 2019 to a low of $78000.0 in Q1 2019.
  • Average Leases over 5 years is $3.8 million, with a median of $4.0 million recorded in 2021.
  • Peak YoY movement for Leases: surged 5941.03% in 2020, then tumbled 35.93% in 2023.
  • A 5-year view of Leases shows it stood at $4.7 million in 2019, then fell by 10.5% to $4.2 million in 2020, then dropped by 10.02% to $3.8 million in 2021, then decreased by 9.88% to $3.4 million in 2022, then tumbled by 32.48% to $2.3 million in 2023.
  • Per Business Quant, the three most recent readings for SYRE's Leases are $2.3 million (Q2 2023), $3.3 million (Q1 2023), and $3.4 million (Q4 2022).